Pulmonary embolism
A pulmonary embolism, or PE, is a sudden blockage in a lung artery. MedlinePlus says it usually happens when a blood clot comes free and is carried in the blood to the lungs, and that the clot is usually a deep vein thrombosis in the leg. It says a PE can be life-threatening, especially with a large clot or several clots. MedlinePlus lists pregnancy and childbirth among the things that raise the risk, and says the risk is highest for about six weeks after childbirth.
Also called PE
- Condition
- In this atlas
Overview
Technical summary
MeSH D011655 is named Pulmonary Embolism; its scope note describes blocking of the pulmonary artery or one of its branches by an embolus. MedlinePlus notes that in rare cases material other than a blood clot, such as air bubbles, fat or parts of a tumor, can block the lung artery.
Recognition
MedlinePlus lists shortness of breath among the symptoms, says a pulmonary embolism can be difficult to diagnose, and says a health care provider will likely order imaging and blood tests.
Burden
No burden claims are published.
Claims and evidence
Context People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages
- Recipient
- Recipient not specified
- Population
- People with the condition each page covers. The pages give no age limits and no inclusion criteria.
- Care setting
- Not stated; patient information pages
- Geography
- Not stated; United States federal health agencies (NLM and NIH)
- Life stage
- Not stated on the pages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive pages)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
MedlinePlus says a pulmonary embolism is a sudden blockage in a lung artery, usually from a blood clot that comes free and is carried to the lungs, and that the clot is usually a deep vein thrombosis in the leg. It says a pulmonary embolism can be life-threatening, especially with a large clot or several clots.
Applies to Recipient not specified People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages
- Certainty method
- Not assessed
- Limitations
- Patient-education pages from US government sources. They give no study, no size of risk and no population, and they do not say how often any of this happens.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
Supports MedlinePlus health topic: Pulmonary Embolism
- Locator
- What is a pulmonary embolism (PE)?, paragraph 1, sentence 1
- How it applies
- MedlinePlus: what a pulmonary embolism is.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
68b1c0a03ff6a4ae8b340c76010bace20ab04f508686ab8aaaa0f40c6e772e82- Reuse basis
- The MedlinePlus page on using its content (fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only) says works produced by the federal government are not copyrighted, and lists summaries on health topic pages and medical test information as public domain; A.D.A.M. Medical Encyclopedia articles are copyrighted, and this atlas cites none. Please acknowledge MedlinePlus, National Library of Medicine, as the source. The raw page is committed in the atlas repository; only the public-domain text is quoted. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only. A second copy was fetched 2026-11-09; the page bytes differ from the 2026-10-30 copy. The treatments section is quoted. The 2026-11-09 copy is committed in the atlas repository. The copy fetched 2026-11-19 is committed in the atlas repository under the same public-domain basis (MedlinePlus reuse page re-fetched 2026-11-19, sha256 1de639e1063fd34ce8fffdbf59a01925be8141980d84ce21292363d217fbc429, hash only).
-
Supports MedlinePlus health topic: Pulmonary Embolism
- Locator
- What is a pulmonary embolism (PE)?, paragraph 1, sentence 2
- How it applies
- MedlinePlus: how it usually happens.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
68b1c0a03ff6a4ae8b340c76010bace20ab04f508686ab8aaaa0f40c6e772e82- Reuse basis
- The MedlinePlus page on using its content (fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only) says works produced by the federal government are not copyrighted, and lists summaries on health topic pages and medical test information as public domain; A.D.A.M. Medical Encyclopedia articles are copyrighted, and this atlas cites none. Please acknowledge MedlinePlus, National Library of Medicine, as the source. The raw page is committed in the atlas repository; only the public-domain text is quoted. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only. A second copy was fetched 2026-11-09; the page bytes differ from the 2026-10-30 copy. The treatments section is quoted. The 2026-11-09 copy is committed in the atlas repository. The copy fetched 2026-11-19 is committed in the atlas repository under the same public-domain basis (MedlinePlus reuse page re-fetched 2026-11-19, sha256 1de639e1063fd34ce8fffdbf59a01925be8141980d84ce21292363d217fbc429, hash only).
-
Supports MedlinePlus health topic: Pulmonary Embolism
- Locator
- What causes a pulmonary embolism (PE)?, paragraph 1, sentence 2
- How it applies
- MedlinePlus: the clot is usually a leg DVT (deep vein thrombosis).
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
68b1c0a03ff6a4ae8b340c76010bace20ab04f508686ab8aaaa0f40c6e772e82- Reuse basis
- The MedlinePlus page on using its content (fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only) says works produced by the federal government are not copyrighted, and lists summaries on health topic pages and medical test information as public domain; A.D.A.M. Medical Encyclopedia articles are copyrighted, and this atlas cites none. Please acknowledge MedlinePlus, National Library of Medicine, as the source. The raw page is committed in the atlas repository; only the public-domain text is quoted. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only. A second copy was fetched 2026-11-09; the page bytes differ from the 2026-10-30 copy. The treatments section is quoted. The 2026-11-09 copy is committed in the atlas repository. The copy fetched 2026-11-19 is committed in the atlas repository under the same public-domain basis (MedlinePlus reuse page re-fetched 2026-11-19, sha256 1de639e1063fd34ce8fffdbf59a01925be8141980d84ce21292363d217fbc429, hash only).
-
Supports MedlinePlus health topic: Pulmonary Embolism
- Locator
- What is a pulmonary embolism (PE)?, paragraph 2, sentence 1
- How it applies
- MedlinePlus: it can be life-threatening.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
68b1c0a03ff6a4ae8b340c76010bace20ab04f508686ab8aaaa0f40c6e772e82- Reuse basis
- The MedlinePlus page on using its content (fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only) says works produced by the federal government are not copyrighted, and lists summaries on health topic pages and medical test information as public domain; A.D.A.M. Medical Encyclopedia articles are copyrighted, and this atlas cites none. Please acknowledge MedlinePlus, National Library of Medicine, as the source. The raw page is committed in the atlas repository; only the public-domain text is quoted. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only. A second copy was fetched 2026-11-09; the page bytes differ from the 2026-10-30 copy. The treatments section is quoted. The 2026-11-09 copy is committed in the atlas repository. The copy fetched 2026-11-19 is committed in the atlas repository under the same public-domain basis (MedlinePlus reuse page re-fetched 2026-11-19, sha256 1de639e1063fd34ce8fffdbf59a01925be8141980d84ce21292363d217fbc429, hash only).
-
Background MeSH scope note for descriptor D011655 (Pulmonary Embolism)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note for pulmonary embolism.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
4056258025fd31cbb5764cd1df3f11b55bd1b5c0b7b048756737e6f6d5462893- Reuse basis
- The NLM web policies page (fetched 2026-10-30, sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Fondaparinux
Applies to Adult Adults for whom the US label of fondaparinux (Arixtra) lists an indication: prophylaxis of deep vein thrombosis after hip fracture, hip replacement, knee replacement or abdominal surgery; treatment of deep vein thrombosis or acute pulmonary embolism
Population, setting and follow-up
- Adult patients described in the indications sections of the label.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passages read state
The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.Limitations. This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Heparin
Applies to Recipient not specified People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Heparin Sodium Injection, in the Fresenius Kabi USA, LLC version dated 2026-04-30 in openFDA, describes heparin as an anticoagulant and lists it for the prophylaxis and treatment of venous thrombosis and pulmonary embolism; the prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or otherwise at risk of thromboembolic disease; atrial fibrillation with embolization; the treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); the prevention of clotting in arterial and cardiac surgery; the prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions, pregnancy and paediatric use and other warnings were not read. Labels differ between sponsors and change over time, and openFDA lists many heparin labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: D-dimer test
Applies to Recipient not specified Patients with suspected pulmonary embolism (narrative review)
Population, setting and follow-up
- Patients with clinically suspected pulmonary embolism, as the review describes them: mostly assessed in the emergency room or as outpatients. The review also discusses older patients, including those over 80, separately.
- Emergency room and outpatient assessment, as described in the review.
- Not stated for the review as a whole.
- Adults are implied but not stated. This record makes no statement about pregnancy, newborns or children.
- Gestational age Not reported
- Postnatal age Not reported
A 2024 narrative review (Journal of Clinical Medicine) says the diagnostic usefulness of D-dimer lies in its high sensitivity and so in its capacity to exclude pulmonary embolism, and that in patients with a non-high clinical probability "a highly sensitive negative D-dimer test safely excludes PE without any additional investigation" (PE is pulmonary embolism). It says that in patients with a high clinical probability the negative predictive value may be insufficient, so D-dimer measurement is not used in them, and that the specificity of the tests for venous thromboembolism is limited.Limitations. A narrative review, not a trial and not a guideline; the statements come from its introduction, which cites other studies. The review's cutoff values, the age-adjusted and probability-adapted cutoffs and the trial figures are not repeated. This is a description of what the review says, not an instruction on when to order or interpret the test.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 105
Record details
- Record id
cardio:pulmonary-embolism- Content hash
dfe407c4a9cd03f9ffbd1619e3e303e3edf66fe887116107e9681a36d03f643a